title: [Application of guidelines for secondary prevention of fracture and the FRAX index in patients with fragility fracture].
abstract: OBJECTIVE
  There are different guidelines for secondary prevention of fractures related with osteoporosis. Our aim is to analyse the appliance of such guidelines in a sample of patients with fragility fracture
  
  
  METHODS
  Adult patients older than 50 years attended in the emergency department with a fragility fracture were invited to participate in a study for secondary prevention. Clinical data and densitometry for the FRAX index were recorded. Current guidelines were employed to calculate the number of patients who needed secondary prevention.
  
  
  RESULTS
  With the appliance of current guidelines to 380 patients, 54-100% of women and 26-81% of men were candidates for treatment. For hip fractures the percentage was 81-100% and for forearm fractures 36-93%. FRAX index for hip fracture was ≥3% in 35% of patients. The National Institute for Health and Clinical Excellence and the National Osteoporosis Foundation 2009 were the most restrictive guidelines (54% and 57% respectively). On the other hand the National Guideline Clearinghouse (87%) and the National Osteoporosis Guideline Group (93%).
  
  
  CONCLUSIONS
  There are high differences in the percentage of patients who need treatment to prevent new fractures according to the guidelines. Fewer patients require treatment when the FRAX index is included in a guideline.
authors.affiliation: Servicio de Reumatología, Hospital Universitario de Gran Canaria Dr. Negrín,. Universidad de Las Palmas de Gran Canaria, España. anarher@gobiernodecanarias.org
authors.forename: Antonio
authors.initials: A
authors.lastname: Naranjo
authors.forename: Soledad
authors.initials: S
authors.lastname: Ojeda-Bruno
authors.forename: Félix
authors.initials: F
authors.lastname: Francisco-Hernández
authors.forename: Celia
authors.initials: C
authors.lastname: Erausquin
authors.forename: Iñigo
authors.initials: I
authors.lastname: Rúa-Figueroa
authors.forename: Carlos
authors.initials: C
authors.lastname: Rodríguez-Lozano
mesh_terms: D015502:Absorptiometry, Photon; D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate / Q000627:therapeutic use; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D002118:Calcium / Q000627:therapeutic use; D005260:Female; D019983:Guideline Adherence / Q000706:statistics & numerical data*; D006620:Hip Fractures / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000150:complications* / Q000188:drug therapy; D058866:Osteoporotic Fractures / Q000209:etiology / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D011885:Radius Fractures / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D012008:Recurrence; D018570:Risk Assessment / Q000379:methods*; D055502:Secondary Prevention / Q000706:statistics & numerical data*; D012720:Severity of Illness Index; D013030:Spain / Q000453:epidemiology; D014458:Ulna Fractures / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D014807:Vitamin D / Q000627:therapeutic use
chemical_list: D050071:Bone Density Conservation Agents; D014807:Vitamin D; D002118:Calcium; D019386:Alendronate